Clofazimine-d7
目录号 : GC45411
An internal standard for the quantification of clofazimine
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Clofazimine-d7 is intended for use as an internal standard for the quantification of clofazimine by GC- or LC-MS. Clofazimine is an antimycobacterial compound with MICs ranging from 0.03 to 0.12 μg/ml against clinical isolates of M. paratuberculosis.1 It also has activity against 80 isolates of M. fortuitum, M. chelonae, and M. fallax (MICs = ≤0.25-8 μg/ml).2 Clofazimine (25 mg/kg per day) reduces the number of M. tuberculosis-infected cells in the spleen and lungs of mice infected with the multidrug-resistant clinical isolate strain CNL.3 Formulations containing clofazimine have been used for the treatment of leprosy and drug-resistant tuberculosis.4
References
1. Chiodini, R.J. Bactericidal activities of various antimicrobial agents against human and animal isolates of Mycobacterium paratuberculosis. Antimicrob. Agents Chemother. 34(2), 366-367 (1990).
2. Ausina, V., Condom, M.J., Mirelis, B., et al. In vitro activity of clofazimine against rapidly growing nonchromogenic mycobacteria. Antimicrob. Agents Chemother. 29(5), 951-952 (1986).
3. Klemens, S.P., DeStefano, M.S., and Cynamon, M.H. Therapy of multidrug-resistant tuberculosis: Lessons from studies with mice. Antimicrob. Agents Chemother. 37(11), 2344-2347 (1993).
4. Szeto, W., Garcia-Buitrago, M.T., Abbo, L., et al. Clofazimine enteropathy: A rare and underrecognized complication of mycobacterial therapy. Open Forum Infect. Dis. 3(3), ofw004 (2016).
| Cas No. | SDF | ||
| Canonical SMILES | ClC(C=C1)=CC=C1NC2=CC3=NC4=CC=CC=C4N(C5=CC=C(Cl)C=C5)C3=C/C2=N\C(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H] | ||
| 分子式 | C27H15Cl2D7N4 | 分子量 | 480.4 |
| 溶解度 | DMSO: slightly soluble,Methanol: very slightly, heated | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0816 mL | 10.408 mL | 20.816 mL |
| 5 mM | 0.4163 mL | 2.0816 mL | 4.1632 mL |
| 10 mM | 0.2082 mL | 1.0408 mL | 2.0816 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。